A Study to Test Different Doses of BI 456906 in Patients With Obesity
Primary Purpose
Obesity
Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
BI 456906
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- Male and female patients ≥ 18 years and < 70 years of age at screening
- Body Mass Index (BMI) ≥ 27 kg/m2 and <40 kg/m2 at screening
- A minimum absolute body weight of 70 kg at screening and a stable body weight (defined as no more than 5% change) 3 months prior to screening
- HbA1c <6.5%
- Further inclusion criteria apply
Exclusion Criteria:
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Supine blood pressure (BP) ≥160/100 mmHg at screening
- Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- Further exclusion criteria apply
Sites / Locations
- Profil Mainz GmbH & Co. KG
- Profil Institut für Stoffwechselforschung GmbH
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
BI 456906
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Cumulative number [N (%)] of patients withdrawn from up-titration by up-titration scheme
Secondary Outcome Measures
AUC0-168 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 168h)
Cmax (maximum measured concentration of the analyte in plasma) after first dose
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03591718
Brief Title
A Study to Test Different Doses of BI 456906 in Patients With Obesity
Official Title
A Phase I, Blinded Within Dose Groups, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Titration Schemes of BI 456906 in Patients With Obesity and Overweight.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
July 26, 2018 (Actual)
Primary Completion Date
April 20, 2020 (Actual)
Study Completion Date
April 30, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
131 (Actual)
8. Arms, Groups, and Interventions
Arm Title
BI 456906
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BI 456906
Intervention Description
Solution for injection
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
solution for injection
Primary Outcome Measure Information:
Title
Cumulative number [N (%)] of patients withdrawn from up-titration by up-titration scheme
Time Frame
Up to 132 days
Secondary Outcome Measure Information:
Title
AUC0-168 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 168h)
Time Frame
Up to 168 hours
Title
Cmax (maximum measured concentration of the analyte in plasma) after first dose
Time Frame
Up to 132 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients ≥ 18 years and < 70 years of age at screening
Body Mass Index (BMI) ≥ 27 kg/m2 and <40 kg/m2 at screening
A minimum absolute body weight of 70 kg at screening and a stable body weight (defined as no more than 5% change) 3 months prior to screening
HbA1c <6.5%
Further inclusion criteria apply
Exclusion Criteria:
Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Supine blood pressure (BP) ≥160/100 mmHg at screening
Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening
Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
Further exclusion criteria apply
Facility Information:
Facility Name
Profil Mainz GmbH & Co. KG
City
Mainz
ZIP/Postal Code
55116
Country
Germany
Facility Name
Profil Institut für Stoffwechselforschung GmbH
City
Neuss
ZIP/Postal Code
41460
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. Studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to: 1.find information in order to request access to clinical study data, for listed studies. 2.request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement'.
Links:
URL
http://www.mystudywindow.com
Description
Related Info
Learn more about this trial
A Study to Test Different Doses of BI 456906 in Patients With Obesity
We'll reach out to this number within 24 hrs